Denali Therapeutics Company
Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Investors
Headquarters:
UK
Funding Status:
IPO
Founded Date:
2015
Last Funding Type:
Series B
Investors Number:
8
Last Funding Date:
2016
Estimated Revenue:
$10M to $50M
Employee Number:
251-500
Total Funding:
347000000
Industry:
Biotechnology, Genetics, Health Diagnostics, Therapeutics